Related Experiment Video

Updated: Jul 19, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Noncoding RNAs in cancer medicine

Laura Cerchia1, Vittorio De Franciscis

  • 1Istituto di Endocrinologia ed Oncologia Sperimentale (IEOS) del CNR G. Salvatore, Naples, Italy.

Journal of Biomedicine & Biotechnology
|October 24, 2006
PubMed

Insights

Artificial small noncoding RNAs (ncRNAs) show promise as cancer therapeutics by targeting oncogenes. These ncRNAs can inhibit gene expression or protein function, offering new avenues for cancer diagnosis and treatment.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Signaling proteins regulating cell growth and differentiation are key targets in cancer due to their oncogenic potential.
  • Artificial small noncoding RNAs (ncRNAs) are emerging as promising therapeutics due to their specificity and low immunogenicity.
  • ncRNAs can modulate gene expression and protein function, making them valuable tools in cancer medicine.

Purpose of the Study:

  • To review innovative methods and applications of ncRNAs in cancer diagnosis and therapy.
  • To highlight the potential of ncRNAs as inhibitors or tracers for cancer treatment.

Main Methods:

  • Review of recent literature on ncRNA development and applications in cancer.
  • Analysis of ncRNA mechanisms including gene silencing and protein antagonism.
  • Exploration of ncRNAs as diagnostic and therapeutic agents.

Main Results:

  • ncRNAs offer high specificity and low immunogenicity for targeted cancer therapy.
  • MicroRNAs (miRNAs) can be utilized for ncRNA gene silencing of oncogenes.
  • Aptamers function as high-affinity ligands and antagonists for disease-associated proteins.

Conclusions:

  • ncRNAs represent a rapidly expanding field with significant potential in cancer medicine.
  • Innovative ncRNA-based strategies offer new possibilities for cancer diagnosis and therapy.
  • Further research into ncRNA applications could revolutionize cancer treatment approaches.

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...